Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow

Biomea Fusion, Inc. (BMEA) presented Phase I results for BMF-650, a potential weight loss drug. The trial met its primary endpoint, showing significant reductions in body weight and waist circumference.

The company plans to advance BMF-650 into a Phase IIb study.